Duloxetine for the Treatment of Dysthymia

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years.

Official Title

Duloxetine for the Treatment of Dysthymia

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. :
    1. * Sign an informed consent form* 18 years of age or older* Females not pregnant or breastfeeding or planning pregnancy and using an acceptable form of contraception* Meet DSM-IV criteria for dysthymia* A screening IDS-C score of 17 or greater* No history of serious or unstable medical disorder* Not taking any significant concurrent medications* Not currently receiving psychotherapy
Exclusion Criteria:
  1. - Suffering from DSM-IV defined* delirium, dementia, amnestic, or other cognitive disorders* mental disorders due to a general medical condition* factitious or somatoform disorders* mental retardation or developmental disabilities* substance or alcohol abuse within the last 3 months* depressive disorders with current suicidal risk* psychotic disorders including delusional disorder, somatic type* dissociative disorder* personality disorders sufficiently severe to interfere with study participation* History of DSM-IV defined bipolar I or II disorder* History of non-response of dysthymia to adequate antidepressant medication* History of major depression refractory to two adequate trials of antidepressants


Lorrin Koran
Elias Aboujaoude, MD, MA
Clinical Professor, Psychiatry and Behavioral Sciences

Contact us to find out if this trial is right for you.


Nona Gamel